News and Trends 12 Apr 2017
Swiss Pharma Clears €37M Funding to Develop a New Class of Antibiotics
Swiss Polyphor has closed a €37M (CHF40M) private funding round to finance the development of its most advanced candidate tackling antibiotic resistances. Polyphor is a clinical stage pharma developing a specific class of so called ‘macrocyclic drugs‘, which are chemically defined by a ring structure. The company’s pipeline is covering a broad range of diseases such as […]